Loading...
Anaplastic thyroid cancer (ATC) is an aggressive variant of thyroid cancer that used to be universally fatal. BRAF V600E mutation is observed in approximately 10% to 50% of patients with ATC; in 2018, the combination of dabrafenib and trametinib (DT) was approved by the FDA based on promising results of a phase 2 study (J Clin Oncol 2018; 36:7) and transformed the care of patients with BRAF V600E-mutated ATC.
A new consensus statement on treatment and management of BRAF V600E-mutated ATC emphasizes rapid identification of BRAF status by immunohistochemistry or polymerase chain reaction followed by timely initiation of systemic therapy. The Thyroid Neck Morbidity Complexity (TNMC) score is used to determine whether neoadjuvant treatment is ne…